Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P407: Faecal calprotectin predicts sustained treatment response of infliximab induction therapy superior to C-reactive protein and clinical activity scores in inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

P.M. Hellström1*, M. Lonnkvist2, H.O. Diaz Tartera1, R. Befrits2, M. Holst3

1Uppsala University, Medical Sciences, Uppsala, Sweden, 2Karolinska Institutet, Medicine, Stockholm, Sweden, 3Karolinska Institutet, Women's and Children's Health, Stockholm, Sweden

P408: Intestinal failure in Crohn’s disease: A case–control studyECCO '18 Vienna
Year: 2018
Authors:

M. Soop1*, A. Bond2, E. Nixon2, A. Teubner1, A. Abraham1, G. Carlson1, S. Lal2

1Irving National Intestinal Failure Unit, Salford Royal NHS Foundation Trust, Surgery, Manchester, UK, 2Irving National Intestinal Failure Unit, Salford Royal NHS Foundation Trust, Gastroenterology, Manchester, UK

P409: Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: Results from a real-world observational studyECCO '18 Vienna
Year: 2018
Authors:

Y. Suzuki1*, T. Hagiwara2, M. Kobayashi2, K. Morita2, T. Shimamoto2, T. Hibi3

1Toho University, Sakura Medical Center, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Sakura-shi, Chiba, Japan, 2AbbVie GK, Tokyo, Japan, 3Kitasato University Kitasato Institute Hospital, IBD Centre, Tokyo, Japan

P410: Has body composition any effect on thiopurine level in IBD?ECCO '18 Vienna
Year: 2018
Authors:

Á. Milassin1*, K. Szántó1, A. Fábián1, R. Bor1, K. Farkas1, A. Bálint1, M. Rutka1, I. Földesi2, A.L. Szijártó3, Z.A. Mezei4, T. Bubán5, F. Nagy1, Z. Szepes1, T. Molnár1, K. Palatka6

1University of Szeged, 1st Department of Internal Medicine, Szeged, Hungary, 2University of Szeged, Institute of Laboratory Medicine, Szeged, Hungary, 3University of Szeged, Department of Medical Physics and Informatics, Szeged, Hungary, 4University of Debrecen, Department of Laboratory Medicine, Debrecen, Hungary, 5University of Debrecen, Department of Internal Medicine, Debrecen, Hungary, 6University of Debrecen, 2nd Department of Internal Medicine, Debrecen, Hungary

P411: Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease centre: Accessibility, resource utilisation and outcomesECCO '18 Vienna
Year: 2018
Authors:

S. Restellini1,2*, I. Morin1, Z. Kurti3, T. Bessissow1, W. Afif1, G. Wild1, E. Seidman1, A. Bitton1, P.L. Lakatos1,3

1McGill University Health Center, Department of Gastroenterology, Montreal, Canada, 2Geneva’s University Hospitals and University of Geneva, Division of Gastroenterology and Hepatology, Geneva, Switzerland, 3Semmelweis University, First Department of Medicine, Budapest, Hungary

P412: White cell count (WCC) and mean corpuscular volume (MCV) as surrogate markers for thiopurine monitoring in inflammatory bowel disease (IBD) treatment: A single-centre experienceECCO '18 Vienna
Year: 2018
Authors:

B. Christopher*, K. Altamimi, N. Campbell, R. Rynne-Lyons, A. Alakkari, A. O'Connor, D. McNamara, N. Breslin, B. Ryan

Adelaide and Meath, Incorporating National Childrens' Hospital, Tallaght, Department of Gastroenterology, Tallaght Hospital, Dublin and Department of Clinical Medicine, TCD, Dublin, Ireland

P413: Relative frequency of relapses in patients with ulcerative colitis and Crohn's disease treated with mesenchymal stromal cells: Five-years of follow-upECCO '18 Vienna
Year: 2018
Authors:

N. Fadeeva1*, O. Knyazev1, A. Kagramanova1, A. Babayan1, A. Lishchinskaya1, I. Ruchkina1, A. Konoplyannikov2, A. Parfenov1

1Moscow Clinical Research Center, Department of Inflammatory Bowel Disease, Moscow, Russian Federation, 2Medical Radiological Scientific Center, Department of Stem Cells Therapy, Obninsk, Russian Federation

P414: Loss of response to anti-TNF in inflammatory bowel disease in a Portuguese centreECCO '18 Vienna
Year: 2018
Authors:

M. Sousa*, A.P. Silva, A. Rodrigues, J. Rodrigues, J. Silva, C. Gomes, L. Proença, J. Carvalho

Centro Hospitalar de Vila Nova de Gaia e Espinho, Vila Nova de Gaia, Portugal

P415: Dose escalation of adalimumab and related prognostic factors in patients with Crohn's disease treated with adalimumab maintenance therapy: A single-centre, five-year cohort studyECCO '18 Vienna
Year: 2018
Authors:

M. Nasuno*, H. Tanaka, K. Sugiyama, M. Miyakawa, S. Motoya

Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan

P416: Metabolite measurement for thiopurine therapy in inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

E. Sánchez Rodríguez*, R. Ríos León, Á. Flores de Miguel, A. Guerrero García, A. Albillos Martínez, A. López Sanromán

Hospital Ramón y Cajal, Servicio Gastroenterología y Hepatología, Madrid, Spain

P417: Crohn disease recurrences: Nothing new under the sun?ECCO '18 Vienna
Year: 2018
Authors:

M. Giulii Capponi*, E. Rausa, M. Lotti, F. Bianco, G. Panyor, A. Indriolo, P. Ravelli, L. Campanati

Papa Giovanni XXIII Hospital, Bergamo, Italy

P418: Predictive factors of surgery in the course of Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

K. Agar*, M. Medhioub, S. Jardak, L. Hamzaoui, A. Khsiba, M.M. Azzouz

Med Taher Maamouri Hospital, GastroEnterology Department, Nabeul, Tunisia

P419: Frequency of inadequate response to anti-tumour necrosis factor therapy in patients with ulcerative colitis. Preliminary results from POLIBD studyECCO '18 Vienna
Year: 2018
Authors:

A. Pekala*, R. Filip

Kliniczny Szpital Wojewódzki nr 2 im. Św. Jadwigi Królowej, Rzeszów and Faculty of Medicine, University of Rzeszów, Poland, Department of Gastroenterology with IBD Unit, Rzeszow, Poland

P420: Effectiveness and safety of biosimilar infliximab (remsima) in a real-life setting in 84 patients with Crohn’s disease and ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

C. Gheorghe1, P. Svoboda2, A. Dimitriu1*, B. Mateescu3, I. Kotzev4

1Fundeni Clinical Institute of Digestive Diseases and Liver Transplantation, Gastroenterology, Bucharest, Romania, 2University Hospital Ostrava, Ostrava, Czech Republic, 3Clinical Hospital Colentina, Bucharest, Romania, 4UMHAT Sveta Marina, Varna, Bulgaria

P421: SER-287, an investigational microbiome therapeutic, induces remission and endoscopic improvement in a placebo-controlled, double-blind randomised trial in patients with active mild-to-moderate ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

B. Misra1, J. Curran2, H. Herfarth3, K. Jagarlamudi4, C. Oneto5, B.R. Bhandari6, G. Wiener7, D. Kerman8, A. Moss9, R. Pomerantz10, J. Zhao10, P. Bernardo10, S. Simmons10, L. Diao10, E. O’Brien10, M. Henn10, M. Trucksis10*

1Borland-Groover Clinic, Jacksonville, USA, 2Community Clinical Research Network, Marlborough, USA, 3University of North Carolina School of Medicine, Chapel Hill, USA, 4PMG Research of Salisbury, Salisbury, USA, 5Concorde Medical Group PLLC, New York, USA, 6Delta Research Partners, Monroe, LA, United States, 7GW Research Inc., Chula Vista, CA, USA, 8University of Miami Hospital, Miami, FL, USA, 9Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA, 10Seres Therapeutics, Cambridge, MA, USA

P422: Sustained corticosteroid-free remission with vedolizumab in moderate-to-severe ulcerative colitis: A post hoc analysis of GEMINI 1ECCO '18 Vienna
Year: 2018
Authors:

E.V. Loftus1, B.E. Sands2, J.-F. Colombel3, I. Dotan4, J.M. Khalid5, D. Tudor6, P. Geransar7*

1Mayo Clinic College of Medicine, Gastroenterology and Hepatology, Rochester, USA, 2Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, USA, 3Gastroenterology, Mount Sinai Hospital, New York, USA, 4Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel, 5Takeda Development Centre Europe Ltd., Evidence and Value Generation, London, UK, 6Takeda Pharmaceuticals International AG, Zurich, Switzerland, 7Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland

P423: Epidemiology, diagnostic work-up and pharmacological requirements of inflammatory bowel disease (IBD) in Spain: Results from the nationwide EpidemIBD study of GETECCUECCO '18 Vienna
Year: 2018
Authors:

M. Chaparro1,2,3,4*, J.L. Cabriada5, M.J. Casanova1,2,4, D. Ceballos6, M. Esteve4,7, H. Fernández8, M. Barreiro-de Acosta9, V. García-Sánchez10,11, D. Ginard12, F. Gomollón4,13,14, R. Llorente Poyatos15, P. Nos4,16, S. Riestra17, M. Rivero18, P. Robledo19, C. Rodríguez Gutiérrez20, B. Sicilia21, E. Torrella22, F. Rodríguez-Artalejo23,24,25, J.P. Gisbert1,2,3,4, on behalf of the EpidemIBD group

1Hospital Universitario de La Princesa, Gastroenterology Unit, Madrid, Spain, 2Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain, 3Universidad Autónoma de Madrid, Madrid, Spain, 4Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain, 5Hospital de Galdakao-Usansolo, Gastroenterology Unit, Vizcaya, Spain, 6Hospital Universitario de Gran Canaria Doctor Negrín, Gastroenterology Unit, Las Palmas de Gran Canaria, Spain, 7Consorci Sanitari Terrassa, Gastroenterology Unit, Tarrasa, Spain, 8Hospital San Pedro, Gastroenterology Unit, Logroño, Spain, 9Hospital Clínico Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 10Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain, 11IMIBIC, Córdoba, Spain, 12Hospital Universitario Son Espases, Gastroenterology Unit, Palma de Mallorca, Spain, 13Hospital Clínico Universitario Lozano Blesa, Gastroenterology Unit, Zaragoza, Spain, 14ISS Aragón, Zaragoza, Spain, 15Hospital General Universitario de Ciudad Real, Gastroenterology Unit, Ciudad Real, Spain, 16Hospital Universitario y Politécnico de La Fe, Gastroenterology Unit, Valencia, Spain, 17Hospital Universitario Central de Asturias, Gastroenterology Unit, Oviedo, Spain, 18Hospital Universitario de Marqués de Valdecilla, Gastroenterology Unit, Santander, Spain, 19Hospital San Pedro de Alcántara, Gastroenterology Unit, Cáceres, Spain, 20Complejo Hospitalario de Navarra, Gastroenterology Unit, Pamplona, Spain, 21Hospital Universitario de Burgos, Gastroenterology Unit, Burgos, Spain, 22Hospital General Universitario Morales Meseguer, Gastroenterology Unit, Murcia, Spain, 23Universidad Autónoma de Madrid, Preventive Medicine and Public Health, Madrid, Spain, 24IdiPAZ, Madrid, Spain, 25Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain

P424: Monitoring response to adalimumab therapy in Crohn’s disease patients by bowel ultrasound: Sub-analysis from TRUSTECCO '18 Vienna
Year: 2018
Authors:

T. Kucharzik1*, C. Maaser2, U. Helwig3, N. Börner4, J. Gronych5, A. Rössler5, S. Rath5, TRUST Study Group

1University Teaching Hospital Lüneburg, Department of Internal Medicine and Gastroenterology, Lüneburg, Germany, 2University Teaching Hospital Lüneburg, Ambulanzzentrum Gastroenterologie, Lüneburg, Germany, 3Gastroenterology Practice, Oldenburg, Germany, 4Gastroenterology Practice, Mainz, Germany, 5AbbVie Deutschland GmbH & Co. KG, Medical Department, Wiesbaden, Germany

P425: Proactive measurement of infliximab trough levels vs. clinical management in inflammatory bowel disease: multicentre studyECCO '18 Vienna
Year: 2018
Authors:

A. Elosua González1*, D. Oyón Lara1, P. Sanz Segura2, M. Arroyo Villariño3, S. García López2, C. Rodríguez Gutiérrez1, Ó. Nantes Castillejo1

1Complejo Hospitalario de Navarra, Gastroenterology, Pamplona, Spain, 2Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain, 3Hospital Clínico Universitario Lozano Blesa, Gastroenterology, Zaragoza, Spain

P426: Meta-analysis of endorectal advancement flap vs. ligation of the intersphincteric fistula tract for Crohn’s and cryptoglandular high perianal fistulasECCO '18 Vienna
Year: 2018
Authors:

M.E. Stellingwerf*, E.M. van Praag, W.A. Bemelman, C.J. Buskens

Academic Medical Center (AMC), Department of Surgery, Amsterdam, The Netherlands